Safety of Once-Daily Ciclesonide Nasal Spray in Children 2 to 5 Years of Age with Perennial Allergic Rhinitis
Authors:
- Kenneth KimKKKenneth Kim
- Michael WeiswasserMWMichael Weiswasser
- Ruediger NaveRNRuediger Nave
- Paul RatnerPRPaul Ratner
- Anjuli NayakANAnjuli Nayak
- Jerry HerronJHJerry Herron
- Nancy HallNHNancy Hall
- Mark WingertzahnMWMark Wingertzahn
- 1 December 2007
- journal article
- research article
- Published by SAGE Publications in Pediatric Asthma, Allergy & Immunology
- Vol. 20 (4) , 229-242
Abstract
Two double-blind studies in children aged 2 to 5 years with perennial allergic rhinitis (PAR) assessed the safety and efficacy of the intranasal corticosteroid ciclesonide. In the first study, 133 patients were randomized to once-daily ciclesonide 25, 100, or 200 μg or placebo for 6 weeks. In the second study, 125 patients were randomized to once-daily ciclesonide 200 μg or placebo for 12 weeks. Safety evaluations included adverse events, nasal examinations, and cortisol levels. Serum concentrations of ciclesonide and its pharmacologically active metabolite, desisobutyryl-ciclesonide (des-CIC), were measured at the end of the 6-week study. Efficacy evaluations included patient/caregiver-assessed 24-hour reflective total nasal symptom scores (TNSS), and physician-assessed nasal symptom scores (PNSS). Ciclesonide was well tolerated, demonstrating a safety profile comparable with placebo. Changes in plasma or urine cortisol levels in patients receiving ciclesonide ≤200 μg/day were not significantly different from placebo or indicative of a treatment-related effect. Systemic exposure to ciclesonide was low. Using a sensitive assay, serum concentrations of ciclesonide and des-CIC were below the lower limit of quantification in many samples. The highest detectable value of des-CIC was 64.5 pg/mL, observed in a patient receiving ciclesonide 25 μg. Although primarily designed to assess safety, both studies displayed evidence of efficacy. In the 12-week study, ciclesonide demonstrated significantly greater reductions in TNSS compared with placebo over the entire treatment period. Intranasal ciclesonide ≤200 μg/day appears to have a favorable safety profile and reduces nasal symptoms in children aged 2 to 5 years with PAR.Keywords
This publication has 29 references indexed in Scilit:
- Once-daily ciclesonide in children: Efficacy and safety in asthmaThe Journal of Pediatrics, 2006
- Ciclesonide, Administered Once Daily, has No Effect on Growth Velocity in Prepubertal Children with Mild, Persistent AsthmaJournal of Allergy and Clinical Immunology, 2006
- Persistence and Effusion Clearance to Esophagus of Ciclesonide in Hypotonic and Isotonic SuspensionsJournal of Allergy and Clinical Immunology, 2006
- Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthmaJournal of Allergy and Clinical Immunology, 2005
- Maintenance of asthma control by once‐daily inhaled ciclesonide in adults with persistent asthmaAllergy, 2004
- Allergic Rhinitis in ChildrenPediatric Drugs, 2004
- The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2003
- Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2002
- Cortisol and ACTH Response to Oral Dexamethasone in Obesity and Effects of Sex, Body Fat Distribution, and Dexamethasone Concentrations: A Dose-Response StudyThe Journal of Clinical Endocrinology & Metabolism, 2002
- Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measures of hypothalamic-pituitary-adrenal–axis activityJournal of Allergy and Clinical Immunology, 1998